BioCentury
ARTICLE | Company News

Sialix in deal with Momenta

October 6, 2012 12:38 AM UTC

Sialix Inc. (Newton, Mass.) granted Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) an option to license a preclinical mAb program against cancer-specific glycans containing N-glycolylneuraminic acid (Neu5Gc). Sialix declined to disclose details. Momenta could not be reached for details. Momenta was off $0.03 to $14.46 on Friday. ...